Duloxetine Capsule, Delayed Release
Product Images NDC 68071-5340

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-5340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 01)

Chemical structure of duloxetine hydrochloride, showing a naphthalene ring connected to a sulfur-containing thiophene ring and an amino methyl group bound as the hydrochloride salt.*

FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 02)

A Kaplan-Meier survival curve showing the proportion of patients with relapse over time (days) from randomization, comparing Duloxetine treatment to placebo. The graph illustrates relapse rates over approximately 200 days, with the Duloxetine group having a lower proportion of relapse compared to placebo.*

FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 03)

A Kaplan-Meier plot showing the proportion of patients with relapse over time (days) from randomization comparing treatment with Duloxetine versus placebo. The x-axis represents time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The graph includes two curves: a solid line for Duloxetine and a dashed line for placebo, indicating a lower relapse proportion with Duloxetine over time.*

FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 04)

A line graph illustrating the percentage of patients improved relative to percent improvement in pain from baseline for different treatments. Four curves represent Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The x-axis shows percent improvement in pain from 0% to 100%, and the y-axis shows the percentage of patients improved from 0% to 90%. The graph compares efficacy of these dosing regimens and placebo over increasing pain improvement thresholds.*

FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 05)

A line graph displaying percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. Three distinct lines represent each treatment, showing trends in pain improvement across a range of percentages.*

FDA Label Image

Fig 5 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 06)

A line graph showing percentage of patients improved by percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, tracking patient-reported pain improvement percentages across increasing pain improvement thresholds from greater than 0% to 100%.*

FDA Label Image

Fig 6 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 07)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two datasets), and placebo. The horizontal axis shows percent improvement in pain, and the vertical axis shows percentage of patients improved.*

FDA Label Image

Fig 7 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 years with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The graph compares Duloxetine 60 mg once daily versus placebo, plotting percent improvement in pain from baseline on the x-axis against the percentage of patients improved on the y-axis.*

FDA Label Image

Figure 8 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows data for Placebo and Duloxetine 60/120 mg once daily, plotting patient improvement percentages on the vertical axis against pain improvement percentages on the horizontal axis.*

FDA Label Image

Figure 9 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 10)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline (BOCF). It compares two groups: placebo and duloxetine 60 mg once daily. The graph shows patient improvement decreasing from about 60% to below 10% as percent improvement increases from >0 to 100.*

FDA Label Image

Figure 10 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 11)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo and Duloxetine 60/120 mg once daily, showing Duloxetine consistently results in higher percentages of improved patients across pain improvement levels.*

FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

Duloxetine 30 mg delayed-release capsules from NuCare Pharmaceuticals, Inc. The image shows a blister pack containing five yellow and black capsules arranged in a cloverleaf pattern with one capsule at the center and the others surrounding it.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Duloxetine 30 mg delayed-release capsules in a blister pack. The capsules are two-toned, pink and white, with at least six capsules shown arranged in a vertical strip. The packaging is labeled with the product name Duloxetine and dosage strength 30 mg, intended for oral use. Manufactured and labeled by NuCare Pharmaceuticals, Inc.*

FDA Label Image

Jpg (68071 5340 9)

The packaging label for Duloxetine 30 mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 90 capsules, capsule identification as D-R, and includes dosing information that each capsule contains 33.7 mg of duloxetine hydrochloride equivalent to 30 mg duloxetine. The label features the NDC 68071-5340-9, storage instructions to keep at 68-77°F, a warning to keep out of reach of children, and manufacturer details including Lupin Limited Goa, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.